Regulatory Setbacks Spark Investor Lawsuits Against Trip.com and ImmunityBio
New Orleans, Wednesday, 6 May 2026.
Following severe regulatory actions—including an antitrust probe and an FDA warning—investors are launching lawsuits against major companies like Trip.com and ImmunityBio after their stocks plummeted over 19 percent.
Antitrust Scrutiny Shakes Trip.com
The foundation of the legal action against Trip.com Group Limited (NasdaqGS: TCOM) rests on allegations of monopolistic practices in China [1]. Trouble began brewing in September 2025, when a market regulator in Zhengzhou summoned the online travel agency over alleged violations involving unfair restrictions on merchant transactions and pricing [1]. The situation escalated significantly on January 14, 2026, when Bloomberg reported that the State Administration for Market Regulation (SAMR) had launched a formal antitrust probe into the company [1]. Regulators allege that Trip.com was “abusing its market position and engaging in monopolistic practices” [1].
ImmunityBio Faces FDA Backlash
In the biotechnology sector, regulatory compliance is the lifeblood of commercial viability [GPT]. For ImmunityBio, Inc. (NasdaqGS: IBRX), a failure to adhere to stringent promotional guidelines has triggered severe legal repercussions [2]. On March 13, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to ImmunityBio’s CEO, Richard Adcock [2]. The agency expressed significant public health concerns over promotional materials—including a podcast and an advertisement—stating they created a “misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer” [2].